Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - estradiol valerate - oral tablet - 1mg

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 1 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; glycerol; povidone; macrogol 6000; magnesium stearate; calcium carbonate; sucrose; titanium dioxide; glycol montanate; maize starch; purified talc; lactose monohydrate - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - estradiol valerate; norethisterone - oral tablet - 1mg ; 1mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - estradiol valerate; norethisterone - oral tablet - 1mg ; 1mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - estradiol valerate; norethisterone - oral tablet - 1mg ; 1mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - estradiol valerate; norethisterone - oral tablet - 1mg ; 1mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - estradiol valerate; norethisterone - oral tablet - 1mg ; 1mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - estradiol valerate; levonorgestrel - oral tablet - 1mg ; 250microgram

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

american regent, inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection is indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause.  when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1.    undiagnosed abnormal genital bleeding. 2.    known, suspected, or history of cancer of the breast. 3.    known or suspected estrogen-dependent neoplasia. 4.    active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5.    active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection, usp is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1.  undiagnosed abnormal genital bleeding. 2.  known, suspected, or history of cancer of the breast. 3.  known or suspected estrogen-dependent neoplasia. 4.  active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5.  active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial   infarction). 6.  live